Beta Bionics shares ‘too cheap’ with estimates going higher, says BofA

BofA notes that Beta Bionics (BBNX) shares were down 22% last week despite Street 2026 revenue estimates having nudged 3.5% higher over the same time frame, adding that last week’s earnings call “was more of a practice run for a newly public company than anything else” given that most of the info on the Q4 call was already known since Beta had already preannounced and set its outlook before going public. With not much having changed fundamentally in the last month, but the stock’s valuation having “materially moved lower,” the stock is now trading at just two times a 2026 revenue estimate that “likely proves materially too low” and the firm also sees the current valuation giving zero credit for the pipeline, pharmacy mix or margin progress, says the analyst, who keeps a Buy rating and $25 price target on shares.